Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis

BACKGROUND: In 2013, denosumab was introduced as peri-operative adjuvant treatment for giant cell tumor (GCT) of bone as it inhibits osteoclast activity. It is suggested that denosumab relives pain, facilitate curettage in lesions requiring resection initially. However, controversy remains whether d...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xi, Li, Hairui, Zhu, Shibai, Wang, Yiou, Qian, Wenwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171828/
https://www.ncbi.nlm.nih.gov/pubmed/32312263
http://dx.doi.org/10.1186/s12891-020-03294-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171828/
https://www.ncbi.nlm.nih.gov/pubmed/32312263
http://dx.doi.org/10.1186/s12891-020-03294-2

Ejemplares similares